Featured Publications

Guidelines for the use of immunotherapy to treat patients with bladder carcinoma were recently published as part of the Society for Immunotherapy of Cancer’s (SITC) Cancer Immunotherapy Guidelines series. It joins guidelines for prostate carcinoma, hematologic malignances, and renal cell carcinoma as a crucial resource developed through multidisciplinary collaboration between academic researchers and physicians, nurses, patients, and patients advocates from throughout the U.S.

The SITC Combination Immunotherapy Task Force white paper published earlier this year, entitled “Combination immunotherapy: a road map” (Ott et al.), aims to identify the most promising prospects for combination therapy and address challenges associated with combinatorial approaches. Building on previous work on combination immunotherapy, this article is the first to address the use of mouse models, safety considerations in early clinical testing, the need for innovative early phase clinical trial designs, and appropriate safety and efficacy endpoints for early phase clinical trials, all in the specific setting of combination immunotherapy.

Article series

Immune monitoring technology primers
Reviewed by the members of the SITC Immune Biomarkers Task Force, these brief primers highlight important aspects of both standardized and novel technologies available in clinical trial settings.

SITC Cancer immunotherapy guidelines
Developed by experts in the treatment of specific types of cancer, each consensus statement provides key indicators to help practicing oncologists determine when and how to best use immunotherapy to treat their patients.​​​​​​​

Articles

September Articles

CASE REPORT

New Content Item
Checkpoint inhibitor is active against large cell neuroendocrine carcinoma with high tumor mutation burden

Large cell neuroendocrine tumor (LCNEC) of the lung is a rare and aggressive tumor similar to small cell lung cancer (SCLC). Thus, it is often treated similarly to… SCLC

Victoria E. Wang, Anatoly Urisman, Lee Albacker, Siraj Ali, Vincent Miller, Rahul Aggarwal and David Jablons

MEETING REPORT

New Content Item

Workshop on challenges, insights, and future directions for mouse and humanized models in cancer immunology and immunotherapy: a report from the associated programs of the 2016 annual meeting for the Society for Immunotherapy of cancer

Understanding how murine models can elucidate the mechanisms underlying antitumor immune responses and advance immune-based drug development is essential to advancing the field...

Andrew Zloza, A. Karolina Palucka, Lisa M. Coussens, Philip J. Gotwals, Mark B. Headley, Elizabeth M. Jaffee, Amanda W. Lund, Arlene H. Sharpe, Mario Sznol, Derek A. Wainwright, Kwok-Kin Wong and Marcus W. Bosenberg

RESEARCH ARTICLE

New Content Item

Durable response rate as an endpoint in cancer immunotherapy: insights from oncolytic virus clinical trials

Traditional response criteria may be insufficient to characterize full clinical benefits of anticancer immunotherapies. Consequently, endpoints such as durable response rate…

Howard L. Kaufman, Robert H. I. Andtbacka, Frances A. Collichio, Michael Wolf, Zhongyun Zhao, Mark Shilkrut, Igor Puzanov and Merrick Ross

RESEARCH ARTICLE

New Content Item

Genetic engineering of human NK cells to express CXCR2 improves migration to renal cell carcinoma

Adoptive natural killer (NK) cell transfer is being increasingly used as cancer treatment. However, clinical responses have so far been limited to patients with hematological malignancies. A potential limiting...

Veronika Kremer, Maarten Ligtenberg, Rosa Zendehdel, Christina Seitz, Annet Duivenvoorden, Erik Wennerberg, Eugenia Colón, Ann-Helén Scherman-Plogell and Andreas Lundqvist

RESEARCH ARTICLE

New Content Item

High-dose interleukin-2 (HD IL-2) for advanced melanoma: a single center experience from the University of Pittsburgh Cancer Institute

Durable remissions are observed in a fraction of metastatic melanoma patients treated with high-dose interleukin-2 (HD IL-2). Early studies reported overall (OR) and…

Diwakar Davar, Fei Ding, Melissa Saul, Cindy Sander, Ahmad A. Tarhini, John M. Kirkwood and Hussein A. Tawbi

RESEARCH ARTICLE

New Content Item

Phase 1 study of intravenous administration of the chimeric adenovirus enadenotucirev in patients undergoing primary tumor resection

Enadenotucirev (formerly ColoAd1) is a tumor-selective chimeric adenovirus with demonstrated preclinical activity. This phase 1 Mechanism of Action study assessed intravenous (IV) delivery…

Rocio Garcia-Carbonero, Ramon Salazar, Ignacio Duran, Ignacio Osman-Garcia, Luis Paz-Ares, Juan M. Bozada, Valentina Boni, Christine Blanc, Len Seymour, John Beadle, Simon Alvis, Brian Champion, Emiliano Calvo and Kerry Fisher

RESEARCH ARTICLE

New Content Item

Viral based vaccine TG4010 induces broadening of specific immune response and improves outcome in advanced NSCLC

Advanced non-small cell lung cancer patients receiving TG4010, a therapeutic viral vaccine encoding human Mucin 1 and interleukin-2 in addition to standard chemotherapy…

Caroline Tosch, Bérangère Bastien, Luc Barraud, Benoit Grellier, Virginie Nourtier, Murielle Gantzer, Jean Marc Limacher, Eric Quemeneur, Kaïdre Bendjama and Xavier Préville

View all articles

Aims and scope

Journal for ImmunoTherapy of Cancer (JITC) is an open access, peer reviewed journal that encompasses all aspects of tumor immunology and cancer immunotherapy, from basic research through to clinical applications.

JITC welcomes submissions to the following sections:

Society affiliation

Free Publication for Society Members

As a way to say thank you to the dedicated Society for Immunotherapy of Cancer (SITC) members who tirelessly work to advance the science and ultimately to improve the lives of patients with cancer, the Society is pleased to offer its members waived article processing charges for manuscripts accepted in JITC through 2016.

JITC Best Paper Awards

Awards were presented during SITC’s 31st Annual Meeting to the first authors of two JITC articles, representing the Best Clinical/Translational and Best Basic Science Papers published in JITC. Congratulations to Zipei Feng, Sachin Puri, and Katherine Woods!

For more information please email info@sitcancer.org, call +1 414 271-2456, or visit http://sitcancer.org/journal.

About SITC

The Society for Immunotherapy of Cancer (SITC) is a 501 (c)(3) non-profit society of medical professionals that was established in 1984 to exchange, encourage and promote information about the promise and breakthroughs of biological therapies, including immunotherapy, for patients with cancer. SITC is the world's leading member-driven society of medical professionals dedicated to advancing cancer immunotherapy through its initiatives, educational sessions, and collaborative endeavors. The Society has become the forum for innovative discussions in the field.

Society members include nearly 1000 influential leaders and scientists engaged in tumor immunology and cancer immunotherapy, including academicians, senior researchers, clinicians, students, government representatives, and industry leaders from around the world. SITC's members represent 17 medical specialties and are engaged in research and treatment of at least a dozen types of cancer.

SITC Mission

It is the mission of the Society for Immunotherapy of Cancer to improve cancer patient outcomes by advancing the science, development and application of immunotherapy through our core values of interaction/integration, innovation, translation and leadership in the field. SITC aims to make cancer immunotherapy a standard of care and the word “cure” a reality for cancer patients everywhere.

Advertisement

JITC logo

Advertisement